<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="472">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04501978</url>
  </required_header>
  <id_info>
    <org_study_id>014 / ACTIV-3</org_study_id>
    <nct_id>NCT04501978</nct_id>
  </id_info>
  <brief_title>ACTIV-3: Therapeutics for Inpatients With COVID-19</brief_title>
  <acronym>TICO</acronym>
  <official_title>A Multicenter, Adaptive, Randomized, Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for Hospitalized Patients With COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>International Network for Strategic Initiatives in Global HIV Trials (INSIGHT)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Copenhagen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical Research Council</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kirby Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Washington D.C. Veterans Affairs Medical Center</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>AIDS Clinical Trials Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>US Department of Veterans Affairs</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>Prevention and Early Treatment of Acute Lung Injury (PETAL)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cardiothoracic Surgical Trials Network (CTSN)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study looks at the safety and effectiveness of different drugs in treating COVID-19 in
      people who have been hospitalized with the infection. Participants in the study will be
      treated with either a study drug plus current standard of care (SOC), or with placebo plus
      current SOC.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a master protocol to evaluate the safety and efficacy of multiple investigational
      agents aimed at modifying the host immune response to SARS-CoV-2 infection, or directly
      enhancing viral control in order to limit disease progression.

      The protocol is for a randomized, blinded, controlled platform study that allows
      investigational drugs to be added and dropped during the course of the study. This allows for
      efficient testing of new drugs against placebo and standard of care (SOC) treatment within
      the same study. When more than one drug is being tested at the same time, participants will
      be randomly allocated to treatments or placebo.

      This platform study involves 2 stages. In stage 1, safety will be evaluated and two
      intermediate outcomes will be assessed to determine whether a drug advances to stage 2.
      Treatments considered to have demonstrated unacceptable risks relative to benefits, or those
      which do not reach the effectiveness threshold for the stage 1 intermediate outcomes, will
      not advance to stage 2. In some cases, stage 1 may include 2 or 3 doses of the same
      investigational drug, which will be considered separate drugs for the purpose of the study.

      Investigational drugs with reasonably well-established safety profiles and evidence of
      effectiveness (i.e. at least equivalent to the criteria for advancement of a drug from stage
      1 to stage 2) may enter the study directly at stage 2. Conversely, for drugs with minimal
      pre-existing safety evidence, the pace of stage 1 will initially be restricted and there will
      be an early review of safety data by an independent Data and Safety Monitoring Board (DSMB).
      A Phase 1 dose escalation study for some investigational drugs may be required, and if so,
      the Phase 1 study would precede stage 1 and be carried out as a separate protocol.

      The international trials within this protocol will be conducted in several hundred clinical
      sites. Participating sites are affiliated with networks funded by the United States National
      Institutes of Health (NIH) and the US Department of Veterans Affairs.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 4, 2020</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pulmonary ordinal outcome (Stage 1)</measure>
    <time_frame>Day 5</time_frame>
    <description>Oxygen requirements measured by 7 categories (1 = least severe, 7 = most severe). The participant's highest (i.e. most severe) observed score is used.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pulmonary+ ordinal outcome (Stage 1)</measure>
    <time_frame>Day 5</time_frame>
    <description>Extrapulmonary complications and respiratory dysfunction measured by 7 categories (1= least severe, 7 = most severe). The participant's highest (i.e. most severe) observed score is used.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time from randomization to sustained recovery (Stage 2)</measure>
    <time_frame>Up to Day 90</time_frame>
    <description>Sustained recovery defined as being discharged from the index hospitalization, followed by being alive and home for 14 consecutive days prior to Day 90.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>Thru Day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite of time to sustained recovery and mortality</measure>
    <time_frame>Thru Day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days alive outside short-term acute care hospital</measure>
    <time_frame>Up to Day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary ordinal outcome</measure>
    <time_frame>Days 1-7, 14 and 28</time_frame>
    <description>Oxygen requirements measured by 7 categories (1 = least severe, 7 = most severe). The participant's highest (i.e. most severe) observed score is used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary+ ordinal outcome</measure>
    <time_frame>Days 1-7</time_frame>
    <description>Extrapulmonary complications and respiratory dysfunction measured by 7 categories (1= least severe, 7 = most severe). The participant's highest (i.e. most severe) observed score is used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in New Early Warning (NEW) Score</measure>
    <time_frame>Baseline to Day 5</time_frame>
    <description>Total of: Respiratory rate (breaths per minute) scored from 0 to +3; Oxygen saturation (%) scored from 0 to +3; Any supplemental oxygen scored from 0 to +2; Temperature scored from 0 to +3; Systolic BP scored from 0 to +3; Heart rate (beats per minute) scored from 0 to +3.; and AVPU (alert, voice, pain, unresponsive) scored from 0 to +3. A higher score denotes a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of clinical organ failure</measure>
    <time_frame>Thru Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite of death or serious clinical COVID-19 related events</measure>
    <time_frame>Thru Day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite of cardiovascular events and thromboembolic events</measure>
    <time_frame>Thru Day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite of grade 3 and 4 clinical adverse events, serious adverse events (SAEs) or death</measure>
    <time_frame>Thru Days 5 and 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of infusion reactions</measure>
    <time_frame>Thru Day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite of SAEs or death</measure>
    <time_frame>Thru Day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in SARS-CoV-2 neutralizing antibody levels</measure>
    <time_frame>Baseline to Days 1, 3, 5, 28 and 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in overall titers of antibodies</measure>
    <time_frame>Baseline to Days 1, 3, 5, 28 and 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in neutralizing antibody levels</measure>
    <time_frame>Baseline to Days 1, 3, 5, 28 and 90</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">10000</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>ACTIV-3 Drug plus SOC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this study will be randomized to receive ACTIV-3 Drug plus Standard of Care (SOC) or placebo plus SOC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo plus SOC</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The placebo arm may be pooled across more than one experimental arm if multiple investigational drugs are available to be tested at the same time. If it is not possible to use matching placebo over more than one experimental arm, additional placebo arms will be included in the study</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3819253</intervention_name>
    <description>Administered by IV infusion</description>
    <arm_group_label>ACTIV-3 Drug plus SOC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Commercially available 0.9% sodium chloride solution. Administered by IV infusion</description>
    <arm_group_label>Placebo plus SOC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Remdesivir</intervention_name>
    <description>Provided to all study participants as SOC unless contraindicated for an individual patient.</description>
    <arm_group_label>ACTIV-3 Drug plus SOC</arm_group_label>
    <arm_group_label>Placebo plus SOC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent.

          -  Positive test for COVID-19 and progressive disease suggestive of ongoing COVID-19
             infection.

          -  Symptoms of COVID-19 for ≤ 12 days.

          -  Require admission to hospital for acute medical care (not for purely public health or
             quarantine purposes).

        Exclusion Criteria:

          -  Patients who have received plasma from a person who recovered from COVID-19 or who
             have received neutralizing monoclonal antibodies at any time prior to hospitalization.

          -  Patients not willing to abstain from participation in other COVID-19 treatment trials
             until after Day 5 of the study.

          -  Any condition which, in the opinion of the responsible investigator, participation
             would not be in the best interest of the participant or that could prevent, limit, or
             confound the protocol-specified assessments.

          -  Patients considered unable to participate in study procedures.

          -  Women of child-bearing potential who are not already pregnant at study entry and who
             are unwilling to abstain from sexual intercourse with men, or practice appropriate
             contraception through Day 90 of the study.

          -  Men who are unwilling to abstain from sexual intercourse with women of child-bearing
             potential or who are unwilling to use barrier contraception through Day 90 of the
             study.

          -  [Stage 1 only] Presence at study enrollment of any of the following:

               1. stroke

               2. meningitis

               3. encephalitis

               4. myelitis

               5. myocardial ischemia

               6. myocarditis

               7. pericarditis

               8. symptomatic congestive heart failure

               9. arterial or deep venous thrombosis or pulmonary embolism

          -  [Stage 1 only] Current or imminent requirement for any of the following:

               1. invasive mechanical ventilation

               2. ECMO (extracorporeal membrane oxygenation)

               3. Mechanical circulatory support

               4. vasopressor therapy

               5. commencement of renal replacement therapy at this admission (i.e. not patients on
                  chronic renal replacement therapy).

        Other investigational drug protocol-defined inclusion/exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Prof. Jens Lundgren</last_name>
    <role>Principal Investigator</role>
    <affiliation>INSIGHT Copenhagen International Coordinating Centre, Rigshospitalet, University of Copenhagen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Prof. James Neaton</last_name>
    <role>Study Chair</role>
    <affiliation>INSIGHT Statistical and Coordinating Centre, University of Minnesota</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>If interested in participating in this study, please contact the appropriate site or</last_name>
    <phone>send email to</phone>
    <email>tico@insight-trials.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Do not include personal information in email. Type ACTIV-3 in subject line.</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Banner University Medical Center Tucson (Site 206-004), 1625 N. Campbell Avenue</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85719</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticopetal@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Community Regional Medical Center (Site 203-005), 2823 Fresno Street</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticopetal@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Keck Hospital of USC (Site 301-020), 1500 San Pablo Street</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticoctsn@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Mount Zion Hospital, UCSF Medical Center (Site 203-007), 1600 Divisadero St.</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticopetal@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>San Francisco VA Healthcare System (Site 074-002), 4150 Clement St.</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticowdc@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Moffitt-Long Hospital, UCSF Medical Center (Site 203-001), 505 Parnassus Ave.</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticopetal@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Stanford University Hospital &amp; Cinics (Site 203-003), 300 Pasteur Dr.</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticopetal@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Colorado Hospital (Site 204-001), 12605 E. 16th Avenue</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticopetal@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Denver Public Health (Site 017-004), 605 Bannock St., MC2600 (Infectious Disease Clinic)</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticowdc@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>MedStar Georgetown University Hospital (Site 067-001), 3800 Reservoir Road NW</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticowdc@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Bay Pines VA Healthcare System (Site 074-004), 10000 Bay Pines Blvd., Bldg. 100, Room 5B-104</name>
      <address>
        <city>Bay Pines</city>
        <state>Florida</state>
        <zip>33744</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticowdc@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Miami VA Healthcare System (Site 074-003), 1201 NW 16 Street</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33125</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACITV-3 in subject line of email and send to</last_name>
      <email>ticowdc@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>The Emory Clinic (Site 301-008), Bldg. A, Suite 2236, 1365 Clifton Rd., NE</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticoctsn@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Kentucky Hospital (Site 210-004), 1000 South Limestone St.</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticopetal@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Ochsner Clinic Foundation (Site 301-015), 1514 Jefferson Highway</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticoctsn@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Maryland (Site 301-019), 22 South Greene Street</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticoctsn@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital (Site 202-002), 55 Fruit Street</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticopetal@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Baystate Medical Center (Site 201-001), 759 Chestnut Street</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <zip>01199</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticopetal@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Michigan (Site 205-001), 1500 East Medical Center Drive</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticopetal@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital (Site 014-001), 2799 W. Grand Blvd.</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticowdc@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hennepin Healthcare (Site 027-001), 701 Park Avenue</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55415</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticowdc@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Mississippi Medical Center (Site 202-005), 2500 North State Street</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticopetal@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Dartmouth-Hitchcock Medical Center/Mary Hitchcock Memorial Hospital (Site 301-024), One Medical Center Drive</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticoctsn@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center Weiler Hospital (Site 206-003), 1825 Eastchester Road</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticopetal@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center Moses Hospital (Site 206-001), 111 E. 210th Street</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticopetal@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Duke University Hospital (Site 301-006), 2301 Erwin Road</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticoctsn@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Health Sciences (Site 210-001), Medical Center Blvd</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticopetal@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation (Site 207-001), 9410 Carnegie Avenue, L15</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticopetal@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation (Site 207-005), 9500 Euclid Avenue</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticopetal@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation (Site 207-006), 9500 Euclid Avenue</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticopetal@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University (Site 208-003), 3181 SW Sam Jackson Park Rd.</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239-3098</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticopetal@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center (Site 212-001), 1211 Medical Center Drive</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticopetal@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>UT Southwestern Medical Center (Site 084-001), 1936 Amelia Court, 2nd Floor</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticowdc@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Baylor, Scott and White Health (Site 301-003), Baylor University Medical Center, 3500 Gaston Ave.</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticoctsn@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Memorial Hermann Hospital (Site 203-006), 6411 Fannin Street</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticopetal@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Michael E. DeBakey Veterans Affairs Medical Center (MEDV AMC) (Site 074-006), 2002 Holcombe Blvd.</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticowdc@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Intermountain Medical Center (Site 211-001), 5121 South Cottonwood Street</name>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticopetal@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Utah Health (Site 211-002), 419 Wakara Way, Suite 207</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticopetal@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Virginia (Site 301-021), 1215 Lee Street</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticoctsn@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Harborview Medical Center (Site 208-001), 325 9th Avenue</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticopetal@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Washington Medical Center - Montlake (Site 208-006), 1959 NE Pacific Street</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticopetal@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>WVU Medicine (Site 301-023), One Medical Center Drive</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26506</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticoctsn@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Aalborg University Hospital (Site 625-005), Hobrovej 18</name>
      <address>
        <city>Aalborg</city>
        <zip>9000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticocph@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Department of Infectious Diseases (Site 625-002), Aarhus University Hospital, Skejby, Palle Juul-Hensens Boulevard 99</name>
      <address>
        <city>Aarhus N</city>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticocph@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Righospitalet (Site 625-006), Blegdamsvej 9,</name>
      <address>
        <city>Copenhagen Ø</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticocph@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Herlev Hospital (Site 625-012), Medicinsk Afdeling, Herlev Ringvej 75</name>
      <address>
        <city>Herlev</city>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticocph@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Nordsjællands Hospital (Site 625-009), Dyrehavevej 29</name>
      <address>
        <city>Hillerød</city>
        <zip>3400</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticocph@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hvidovre Hospital (Site 625-001), Department of Infectious Diseases, Kettegård allé 30</name>
      <address>
        <city>Hvidovre</city>
        <zip>2650</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticocph@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Medicinsk Afdeling (Site 625-011), Kolding Sygehus, Sygehusvej 24</name>
      <address>
        <city>Kolding</city>
        <zip>6000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticocph@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Odense Universitetshospital (Site 625-004), Infektionsmedicinsk Forskningsenhed,J.B. Winsløwsgade 4</name>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticocph@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Tan Tock Seng Hospital (Site 612-201), National Centre for Infectious Diseases (NCID), 11 Jalan Tan Tock Seng</name>
      <address>
        <city>Singapore</city>
        <zip>308433</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticosyd@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Singapore</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <link>
    <url>https://www.cdc.gov/coronavirus/2019-nCoV/index.html</url>
    <description>CDC (Centers for Disease Control and Prevention): Coronavirus (COVID-19) website</description>
  </link>
  <link>
    <url>https://www.niaid.nih.gov/clinical-trials/participant-guide</url>
    <description>A Participant's Guide to Clinical Trials (NIAID)</description>
  </link>
  <link>
    <url>https://www.niaid.nih.gov/clinical-trials/find-a-clinical-trial</url>
    <description>Find a Clinical Trial (NIAID)</description>
  </link>
  <link>
    <url>https://www.niaid.nih.gov/clinical-trials</url>
    <description>Clinical Trials at NIAID</description>
  </link>
  <link>
    <url>https://www.niaid.nih.gov/</url>
    <description>National Institute for Allergy and Infectious Diseases (NIAID)</description>
  </link>
  <link>
    <url>https://www.covid19treatmentguidelines.nih.gov/</url>
    <description>NIH COVID-19 treatment guidelines</description>
  </link>
  <link>
    <url>https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/patient-management</url>
    <description>WHO COVID-19 treatment guidelines</description>
  </link>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>August 3, 2020</study_first_submitted>
  <study_first_submitted_qc>August 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 6, 2020</study_first_posted>
  <last_update_submitted>October 2, 2020</last_update_submitted>
  <last_update_submitted_qc>October 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>COVID 19</keyword>
  <keyword>Coronaviridae Infections</keyword>
  <keyword>Coronavirus Infections</keyword>
  <keyword>RNA Virus Infections</keyword>
  <keyword>Virus Diseases</keyword>
  <keyword>Nidovirales Infections</keyword>
  <keyword>SARS-CoV-2</keyword>
  <keyword>SARS Coronavirus</keyword>
  <keyword>ACTIV-3</keyword>
  <keyword>ACTIV3</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

